JJP Biologics
Business Services · Poland · 1-10 Employees
View Company Info for Free
Overview
Headquarters
Bobrowiecka 6, Warsaw, Masovian Voivodes...Website
www.jjpbiologics.comRevenue
<$5 MillionIndustry
About JJP Biologics
Is JJP Biologics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once JJP Biologics has new funding data
Check out if JJP Biologics is spiking on competitors!
Earning: See what the market has to say on JJP Biologics recently announced quarterly report
JJP Biologics, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at JJP Biologics
Website visits: Recent activity has been detected on your website
Check if JJP Biologics has recently received funding, and reach out quickly before it becomes old news!
Click to see if JJP Biologics had a recent Job posting/layoffs
Product Launch: Get notified when JJP Biologics launches new products
Recommended Actions
Reach out to Masked Content who joined JJP Biologics as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
JJP Biologics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
JJP Biologics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about JJP Biologics.
JJP Biologics Tech Stack
A closer look at the technologies used by JJP Biologics
JJP Biologics News & Media
Correction: JJP Biologics Announces Positive Top-Line Phase I Trial Results of JJP-1212, its anti-CD89 antagonist
Warsaw, Poland – January 7, 2026 – JJP Biologics, a clinical-stage biotechnology company that specializes in the development of innovative biologics, today announces positive top-line results from its Phase I clinical trial of JJP-1212, a potential first-in-class anti-CD89 antagonist that is being developed to treat autoimmune, inflammatory, and fibrotic diseases where pathogenic IgA autoantibodies are a key part of the disease mechanism.JJP Biologics Announces Positive Top-Line Phase I Trial Results of JJP-1212, its anti-CD89 antagonist
Warsaw, Poland – January 7, 2026 – JJP Biologics, a clinical-stage biotechnology company that specializes in the development of innovative biologics, today announces positive top-line results from its Phase I clinical trial of JJP-1212, a potential first-in-class anti-CD89 antagonist that is being developed to treat autoimmune, inflammatory, and fibrotic diseases where pathogenic IgA autoantibodies are a key part of the disease mechanism.JJP Biologics Announces Positive Decision to Execute a First-in-Human Clinical Trial of Anti-Inflammatory mAb JJP-1212 (anti-CD89)
WARSAW, Poland--(BUSINESS WIRE)-- #FirstinHuman--JJP Biologics is the first Polish company to receive approval of the First-in-Human clinical trial with a novel therapeutic monoclonal antibody
Top Business Services Companies
Frequently Asked Questions Regarding JJP Biologics
JJP Biologics is an innovative Polish biotechnology company focused on developing novel biological therapeutics in conjunction with established companion diagnostics. Their pipeline includes early-stage programs targeting various disease indications, such as autoinflammatory diseases and solid tumors. The company aims to collaborate with investors... Read More